

Figure S1. Therapeutic guideline for head and neck cancer in our institution

Squamous Cell Carcinoma of Head and Neck (SCCHN)	→ Resectable, Oral Cavity	→ Surgery	No following risk factor	→ Observation	p.3
			Tongue cancer with extrinsic muscle extension; pT4 (exclude tumor >4cm and DOI >10mm), or pT3N1, or pT1-2N1 (level IV/V), or close margin ≤ 2mm, or poorly differentiation with tumor depth ≥ 4mm, or =2 minor risk factors	→ Adjuvant RT	
			ENE (+), or margin (+), or ≥ pN2b, or ≥ 3 minor risk factors	→ Adjuvant CCRT	
	→ Unresectable/Inoperable/ Low surgical curability, Oral Cavity	→ CCRT → Bio -radiotherapy → Neoadjuvant CT → CCRT or Bio -radiotherapy			p.4-5
	→ Resectable, Oropharynx/Hypopharynx/Larynx	→ Surgery	No following risk factor	→ Observation	p.6
			pT4, or pT3N1, pT1-2N1 (level IV/V) or close margin ≤ 2mm, or poorly differentiation, or = 2 minor risk factors	→ Adjuvant RT	
			ENE (+), or margin (+), or pN2b, or ≥ 3 minor risk factors	→ Adjuvant CCRT	
	→ Resectable, Oropharynx /Hypopharynx/Larynx	→ Endoscopic surgery or RT alone → CCRT → Bio -radiotherapy			p.7-10
	→ Unresectable/Inoperable/Low surgical curability, Oropharynx/Hypopharynx/Larynx	→ CCRT → Bio -radiotherapy → Neoadjuvant CT → CCRT or Bio -radiotherapy			p.11-12
	→ Recurrent/metastatic (if not considered with surgery or radiotherapy)	→ CT, Molecular Targeted therapy, Immuno-Oncologic therapy → Clinical trials			p.13